Please assess the completion status of the following clinical trial:

Trial Title: Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years.~* Informed consent.~* Possession of a working smart phone that participant is able to independently use.~* Smartphone to support iOS versions 10.0 and newer or to support Android versions 5.0 (Lollipop) and newer.~* Smartphone to have minimum storage space required to install the digital diary: 250MB.~* Smartphone must have enough memory to run the digital diary.~* Either:~* Participant account of a diagnosis of hypertension consistent with NICE/BIHS criteria on either 24h ABPM or repeated home measures of blood pressure, ideally prior to treatment.~Or •Current treatment with antihypertensive medication.~For the intervention study cohort~* Sub-optimal blood pressure control defined as average systolic blood pressure of 140mmHg or greater, and/or average diastolic blood pressure of 90mmHg or greater during the 5 days run-in period.~* Stable antihypertensive medication during assessment of eligibility.~For the observational study cohort~• Average systolic blood pressure of less than 140mmHg and average diastolic blood pressure of less than 90mmHg during the 5 days run-in period~Exclusion Criteria:~* Current infection, or symptoms suggestive of SARS-2 COVID-19 at the time of screening (rescreening when recovered is allowed).~* Known severe adverse reaction to amlodipine.~* Currently receiving \>=10mg /day amlodipine.~* Participation in another clinical trial, where the participant has received IMP in the last three months, with the exception of the MRC Aim-Hy study (IRAS: 199550, REC: 16/EE/0294) where participants can be screened after 6 weeks from final visit.~* Pregnant or lactating or female of childbearing\* potential not using adequate contraception (defined as oral contraceptive pill, IntraUterine Device, double barrier methods or abstinence as a clearly defined lifestyle choice).~* Participants who have too limited or no understanding of spoken and/or written English in the opinion of the investigator~* Participants who have hypersensitivity to dihydropyridine derivatives, amlodipine or to any of the excipients.~* Participants with obstruction of the outflow tract of the left ventricle (e.g. high grade aortic grade stenosis).~* Participants with a known intolerance of fructose, sugar, glycerol, maltitol liquid.~(Liquid amlodipine is classed as sugar free, whereas the standard tablet contains lactose).~* Co-morbidities incompatible with study participation e.g. that result in a participant being unable to complete daily entries satisfactorily via his/her smart phone.~* Participants lacking capacity .~* Unstable Heart failure (e.g. after myocardial infarction).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interventional (Type: EXPERIMENTAL): Intervention group will receive Amlodipine 1mg/ml Oral Solution; starting dose 1-2mg per day for patients not on amlodipine at entry. Participants will take the prescribed dosage daily. Dosage will be reviewed on a fortnightly basis and adjusted as necessary. The total duration is 3 months.
- Observational (Type: NO_INTERVENTION): This group will record blood pressure readings and data on a daily basis for a total of 3 months. They will not take any medication. They will be reviewed on a monthly basis in consultations.

Based on this trial design, predict the completion outcome and termination type (if applicable).